Reneo Pharmaceuticals reports Q3 EPS (53c), consensus (57c)

"We continued to advance our REN001 development programs during the third quarter," said Gregory J. Flesher, President and CEO of Reneo Pharmaceuticals. "As of today, we have achieved over 80% enrollment in the ongoing pivotal STRIDE study in primary mitochondrial myopathy patients with mitochondrial DNA defects. We remain on track to announce topline data from this study in the fourth quarter of 2023. Moreover, we are pleased that the majority of patients who completed STRIDE are electing to enroll into the long-term STRIDE AHEAD safety study. Furthermore, we announced positive results from the Phase 1b study in long-chain fatty acid oxidation disorders patients with nuclear DNA defects. Finally, we are now in the process of planning both a Phase 2 study in LC-FAOD patients and a study in PMM patients with nDNA defects," concluded Mr. Flesher.